Lurtz M M, Hareland M L, Pedersen S E
Department of Molecular Physiology and Biophysics, Baylor College of Medicine, Houston, Texas 77030, USA.
Biochemistry. 1997 Feb 25;36(8):2068-75. doi: 10.1021/bi962547p.
Quinacrine is a noncompetitive antagonist of the nicotinic acetylcholine receptor (AChR) which displays severalfold fluorescent enhancement upon binding to AChR-rich membranes from Torpedo californica electric organ. It is demonstrated that the fluorescence enhancement comprises two components: specific interaction at a high-affinity binding site on the AChR, and interaction with the lipid bilayer. The interaction with the lipid bilayer can be attenuated by other noncompetitive antagonists, but at concentrations substantially higher than those required for binding to the AChR. It is further shown that quinacrine can inhibit the binding of [3H]phencyclidine and [3H]ethidium in a manner fully consistent with simple competitive inhibition. The data support a model for high-affinity quinacrine binding to the same, single locus of the acetylcholine receptor as phencyclidine and ethidium. This site is likely within the lumen of the ion channel.
喹吖因是烟碱型乙酰胆碱受体(AChR)的非竞争性拮抗剂,它与来自加州电鳐电器官富含AChR的膜结合后会呈现出数倍的荧光增强。结果表明,荧光增强包括两个部分:在AChR上高亲和力结合位点的特异性相互作用,以及与脂质双层的相互作用。与脂质双层的相互作用可被其他非竞争性拮抗剂减弱,但所需浓度远高于与AChR结合所需的浓度。进一步研究表明,喹吖因能够以完全符合简单竞争性抑制的方式抑制[3H]苯环利定和[3H]乙锭的结合。这些数据支持了一个模型,即喹吖因与苯环利定和乙锭一样,以高亲和力结合到乙酰胆碱受体的同一单一位点。该位点可能位于离子通道腔内。